Inovio Pharmaceuticals Inc Stock NYSE
Stocks
US45773H1023
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 07-30 | Top Premarket Decliners | MT |
| 07-03 | Inovio Pharmaceuticals Files $300 Million Mixed Shelf Offering | MT |
| Market Cap | 54.56M 47.37M 44.17M 40.57M 76.74M 5.19B 77.58M 521M 204M 2.59B 205M 200M 8.6B | P/E 2026 * |
-0.75x | P/E 2027 * | -1.63x |
|---|---|---|---|---|---|
| Enterprise Value | 54.56M 47.37M 44.17M 40.57M 76.74M 5.19B 77.58M 521M 204M 2.59B 205M 200M 8.6B | EV / Sales 2026 * |
81.8x | EV / Sales 2027 * | 1.06x |
| Free-Float |
99.62% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Inovio Pharmaceuticals Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Jacqueline Shea
CEO | Chief Executive Officer | 60 | 10/05/2022 |
Peter Kies
DFI | Director of Finance/CFO | 62 | 01/06/2002 |
Michael Sumner
CTO | Chief Tech/Sci/R&D Officer | 60 | 27/06/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Simon Benito
CHM | Chairman | 81 | 03/01/2019 |
David Weiner
BRD | Director/Board Member | 69 | 11/03/2016 |
Wendy Yarno
BRD | Director/Board Member | 71 | 06/12/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.25% | -3.41% | -0.43% | +13.26% | 48B | |
| +6.03% | +5.22% | +420.33% | +519.87% | 41.13B | |
| -2.21% | -6.07% | +24.87% | +5.20% | 37.56B | |
| +2.94% | -2.25% | +6.15% | +59.69% | 35.91B | |
| +1.98% | +4.74% | +12.19% | +41.37% | 29.86B | |
| +0.47% | -3.87% | - | - | 16.12B | |
| +0.31% | +0.72% | +32.99% | +122.25% | 16.05B | |
| +0.96% | +1.25% | +4.35% | +18.36% | 13.76B | |
| -0.98% | -12.98% | -4.82% | -38.09% | 12.1B | |
| Average | +1.35% | -1.81% | +61.95% | +92.74% | 27.83B | |
| Weighted average by Cap. | +1.76% | -0.93% | +82.42% | +116.68% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 667K 579K 540K 496K 938K 63.42M 948K 6.36M 2.49M 31.7M 2.5M 2.45M 105M | 51.31M 44.55M 41.54M 38.16M 72.16M 4.88B 72.96M 490M 191M 2.44B 193M 188M 8.08B |
| Net income | -71.79M -62.33M -58.12M -53.39M -101M -6.83B -102M -685M -268M -3.41B -270M -264M -11.31B | -56.74M -49.26M -45.93M -42.2M -79.8M -5.4B -80.68M -542M -212M -2.7B -213M -208M -8.94B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
